ArticleACR open rheumatology2026
A Novel Use of Anifrolumab for a Novel Disease.
Article in ACR open rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo explore the potential role of type-I interferon (IFN-I) signaling in autoimmune cytopenias outside the context of systemic lupus erythematosus (SLE), and to evaluate the clinical response to off-label anifrolumab in two patients with fatigue and immune-mediated cytopenias who did not meet established criteria for SLE.
methodsWe describe two older White male patients with fatigue and autoimmune cytopenias who did not meet established SLE criteria and were refractory to standard immunosuppressants. Both received off-label anifrolumab.
resultsBoth patients experienced rapid and sustained improvement in fatigue and resolution of cytopenias following treatment, with continued benefit and no significant adverse effects.
conclusionThese cases suggest IFN-I signaling may underlie autoimmune cytopenias outside classic SLE. The positive response to anifrolumab raises the possibility of an atypical or distinct IFN-mediated autoimmune condition and supports broader investigation of IFN blockade in hematologic autoimmunity.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.